Incyte (INCY) and Mirum Pharmaceuticals (MIRM) said Thursday they will present pivotal phase 2 data for zilurgisertib to treat fibrodysplasia ossificans progressiva, or FOP, at the Endocrine Society's annual meeting later this month in Chicago.

"These data add to the growing clinical understanding of zilurgisertib's potential in FOP as Incyte and Mirum continue to advance toward the FDA's priority review PDUFA date" on Sept. 26, said Incyte's chief medical officer Steven Stein.

Incyte shares were 0.7% higher in premarket trading, while Mirum was up 0.2%